Calculating the ratio between serum triglyceride and apolipoprotein B levels may help rule out patients with hypertriglyceridemia who are at low risk of developing hypertriglyceridemic pancreatitis ...

STOCKHOLM, May 26, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza® (olezarsen) reduced the relative ...

A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of ...

NEW ORLEANS — When added to standard lipid-lowering therapy, olezarsen, a drug approved in 2024 for patients with familial chylomicronemia syndrome, significantly lowered triglycerides and reduced the ...

Please provide your email address to receive an email when new articles are posted on . Nonfasting mild-to-moderate hypertriglyceridemia was linked to a higher risk for acute pancreatitis and ...

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by ...

About 10% of reported cases of acute pancreatitis are associated with hypertriglyceridemia. Plasmapheresis has been shown to reduce serum triglyceride levels, and current guidelines recommend its use ...

Hypertriglyceridemia can lead to a substantial discordance in measured (TCO 2) and calculated (HCO 3) serum bicarbonate levels on serum electrolyte testing and blood gases, respectively.

Arrowhead now continues to advance plozasiran toward potential regulatory approval in severe hypertriglyceridemia. ・A possible approval will place Arrowhead directly against Ionis Pharmaceuticals, ...

Background A 53-year-old man with a history of hypertension and gout was referred to our clinic for severe hypertriglyceridemia, diagnosed 3 years previously. He was asymptomatic and had no history of ...

STOCKHOLM, May 26, 2026 /PRNewswire/ -- Sobi (STO: SOBI) today announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza (olezarsen) reduced the relative ...